Serological Strategy to Optimize Prognostic Stratification in Myocardial Infarction

Overview

About this study

Identify novel molecular targets associating clinical findings with ‘omics outputs to create a serum-based approach prognostic of patient baseline MI propensity at the time of MI-related injury

Identify novel molecular targets associating clinical findings with ‘omics outputs to create a serum-based approach prognostic of heart failure vulnerability at the time of MI-related injury

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years of age or older
  •  ST-elevation MI
  • Non-ST elevation MI

Exclusion Criteria:

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Atta Behfar, M.D., Ph.D.

Open for enrollment

Contact information:

Paul Stalboerger M.S., PMP

(507)538-6776

stalboerger.paul@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20307519

Mayo Clinic Footer